Date posted:
07/08/2025
Theolytics is pioneering a new approach to cancer treatment using oncolytic viruses, viruses that selectively infect and destroy tumour cells. With support from the Innovate UK Cancer Therapeutics programme, the company is targeting ovarian cancer, a disease with limited treatment options and high unmet need.
Innovate UK funding enabled Theolytics to move from lab-based research to a first-in-human clinical trial for patients with advanced ovarian cancer.
The mission of the company is to improve the lives of cancer patients and their families. The funding from the Innovate UK Cancer Therapeutics programme enables us to evaluate our lead candidate in the clinic and provides the opportunity to advance a new therapeutic option for patients with a very high unmet need.
Dr Margaret Duffy, CSO and Co-founder
